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Abstract
Purpose Hybrid image-guided surgery technologies such as combined radio- and fluorescence-guidance are increasingly gaining
interest, but their added value still needs to be proven. In order to evaluate if and how fluorescence-guidance can help realize
improvements beyond the current state-of-the-art in sentinel node (SN) biopsy procedures, use of the hybrid tracer indocyanine
green (ICG)-99mTc-nancolloid was evaluated in a large cohort of patients.
Patients and methods A prospective trial was conducted (n = 501 procedures) in a heterogeneous cohort of 495 patients with
different malignancies (skin malignancies, oral cavity cancer, penile cancer, prostate cancer and vulva cancer). After injection of
ICG-99mTc-nanocolloid, SNs were preoperatively identified based on lymphoscintigraphy and SPECT/CT. Intraoperatively, SNs
were pursued via gamma tracing, visual identification (blue dye) and/or near-infrared fluorescence imaging during either open
surgical procedures (head and neck, penile, vulvar cancer and melanoma) or robot assisted laparoscopic surgery (prostate cancer).
As the patients acted as their own control, use of hybrid guidance could be compared to conventional radioguidance and the use
of blue dye (n = 300). This was based on reported surgical complications, overall survival, LN recurrence free survival, and false
negative rates (FNR).
Results A total of 1,327 SN-related hotspots were identified on 501 preoperative SPECT/CT scans. Intraoperatively, a total
number of 1,643 SNs were identified based on the combination of gamma-tracing (>98%) and fluorescence-guidance (>95%). In
patients wherein blue dye was used (n = 300) fluorescence-based SN detection was superior over visual blue dye-based detection
(22–78%). No adverse effects related to the use of the hybrid tracer or the fluorescence-guidance procedure were found and
outcome values were not negatively influenced.
Conclusion With ICG-99mTc-nanocolloid, the SN biopsy procedure has becomemore accurate and independent of the use of blue
dye. With that, the procedure has evolved to be universal for different malignancies and anatomical locations.
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Introduction
Sentinel node (SN) biopsy is a routine procedure in the man-
agement of breast cancer and melanoma, where it allows for
loco-regional staging of lymph nodes (LNs) [1, 2]. This pro-
cedure is also more and more applied as a staging-tool for
other cancers, e.g. prostate and penile cancer [3, 4]. For the
identification of SNs, targeting nanoparticles entitled
radiocolloids (e.g. 99mTc-nanocolloid) are considered the stan-
dard. The migration kinetics and accumulation of
radiocolloids in individual lymphatic basins can be mapped
in a non-invasive manner using lymphoscintigraphy and
SPECT/CT [5]. For intraoperative tracing of radiocolloid con-
taining SNs, a portable gamma camera or more common a
gamma probe can be used [6].
For the surgeons convenience, however, the radioguidance
approach is often strengthened by optical guidance in the form
of blue dye [7]. Unfortunately, blue dye also has some short-
comings, the main ones being the staining of the injection site,
allergic reactions and the limited degree of nodal identification
[8]. The last is a result of the lack of SNs specificity of this
lymphangiographic agent and the limited sensitivity of this
light-absorbance based detection method. Almost two de-
cades ago, the fluorescent dye indocyanine green (ICG) was
introduced as an alternative lymphangiographic dye [9]. At
high concentrations ICG is green in color, but at low concen-
trations it can only be detected using dedicated near-infrared
fluorescence cameras (maximum emission intensity =
820 nm) [10]. One of the advantages, compared to blue dye
is the superior penetration depth of the fluorescence emission
(up to 1 cm). Nevertheless, this penetration depth is vastly
inferior to the >10 cm penetration of a radioactive signature of
99mTc [11]. Furthermore, as a result of its molecular size, ICG
still shares a shortcoming with blue dye, namely, an unrestrict-
ed lymphatic migratory pattern and with that a lack of speci-
ficity for SNs compared to higher echelon nodes. This same
feature also induces spillages during surgical manipulations of
the tissue.
In an ideal situation, the best features related to both the
radioguided surgery and optical guidance procedures would
be integrated, meaning SN specificity should be combined
with sensitive intraoperative optical guidance. Such a best-
of-both-worlds scenario was realized following the develop-
ment of the hybrid tracer, ICG-99mTc-nanocolloid and its clin-
ical translation in 2009 [12]. In various malignancies this hy-
brid tracer was shown to allow: (1) non-invasive preoperative
localization of the SNs using scintigraphy and or SPECT/CT,
(2) intraoperative rough localization based on the gamma sig-
nal and/or using radioguidance based navigation approaches,
and (3) detailed superficial (< 1 cm) intraoperative fluores-
cence guidance [13–16].
Promising new surgical guidance technologies using radio-
and fluorescence-imaging are gaining interest from a
scientific, medical and industrial perspective. However, trans-
lation of such technologies generally has been restricted to
first-in-human trials with small patient groups and in special-
ized academic hospitals [11]. Internal controls and follow up
of patients and outcome data for larger and more heteroge-
neous patient groups are essential to benchmark new technol-
ogies and assess their added value over the state-of-the-art.
This study presents the validation of the ICG-99mTc-
nanocolloid based hybrid SN procedure in a relatively large
(495 patients) and heterogeneous patient group (skin malig-
nancies, oral cavity cancer, penile cancer, prostate cancer and
vulva cancer) and includes both follow-up and outcome data.
By relating the hybrid procedure to the traditional
radioguidance and blue dye approaches, in the same patient
(Fig. 1), the added value of the new technology was investi-
gated/determined.
Methods
Between March 2010 and January 2016, 495 patients were
prospectively included in 501 SN procedures (some patients
were scheduled for re-resections including SN procedure). Of
this group 234 patients (47%) were previously included in
different studies [5, 13–16]. All patients were operated at the
Netherlands Cancer Institute – Antoni van Leeuwenhoek
Hospital. Approval for these studies was obtained from the
local institution review board and the trials was registered
under reference NL26699.031.09 and NL40636.031.12.
Following initial examination in a trail context, off-label use
of the hybrid tracer was approved by the local pharmacy (ap-
proval received in November 2012). This was only allowed in
indications were the SN procedure is considered standard of
care in our hospital.
Patients
All included patients were ≥ 18 years of age and had a histo-
logically proven malignancy (See Supplemental information
(SI), Table SI1). All patients were regional clinically node-
negative (cN0) as defined by palpation and ultrasound-
guided fine-needle aspiration cytology. Patients with squa-
mous cell carcinoma (SCC) of the penis and vulva were also
eligible when cN1 was on the contralateral side. All patients
underwent SN biopsy and subsequent treatment of the primary
tumor site.
The fully prepared hybrid tracer (ICG-99mTc-nanocolloid)
was commercially obtained from the Dutch GE Healthcare
radiopharmacy (Leiderdorp, The Netherlands). Injection pro-
cedure, preoperative imaging procedure, surgical procedures
and pathological examination have been reported previously
and are explained in more detail in the supporting information
section [5, 13–16].
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The order wherein the surgical guidance technologies were
used were in agreement with a previously described protocol
[14]. In brief, prior to the start of SN resection, in open pro-
cedures a portable gamma camera (Sentinella; Oncovision,
Valencia, Spain) and gamma probe (Neoprobe; Johnson &
Johnson Medical, Hamburg, Germany) were used to assess
the distribution of the SNs in the surgical field. This was
followed by a directed incision and the application of SNs
using a (laparoscopic) gamma probe (Europrobe,
Strassbourg, France). When blue dye was administered, blue
coloration was used to identify the location of tumor
draining lymphatic vessels and blue dye containing SNs.
Finally, fluorescence imaging was performed to confirm the
location of the SNs in high resolution and to support their
surgical resection (PhotoDynamic Eye; Hamamatsu
Photonics, Hamamatsu, Japan or 30° laparoscope HOPKINS
II 10 mm; Karl Storz Endoskope GmbH, Tuttlingen,
Germany). This order helps identify the added value provided
by fluorescence guidance on top of the traditional radio- and
blue dye guidance. While this approach ensures optimal pa-
tient care, a down side is that it does makes it more complex to
isolate the independent value that fluorescence guidance
brings to the operating surgeon.
To verify nodal removal, the surgical wound was
reexamined using radiotracing/imaging, fluorescence imag-
ing, visual inspection for blue dye and palpation (when
Fig. 1 Radioguidance enabled by the hybrid tracer. The first three rows
presents open surgical procedures (head and neck area, trunk and groin),
while the last row presents a laparoscopic procedure (pelvis). The second
and third column display examples of preoperative lymphoscintigraphy
and SPECT/CT illustrating drainage to the neck, axilla, groin and pelvis.
The last column gives an indication of the radioguidance technologies
used intraoperatively
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possible). When a residual signal was observed at the location
of the original SN, this node was considered a missed SN or
part of a cluster of multiple adjacent SNs and was removed. In
case of clustered nodes, after the operation, the acquired
SPECT and CT images were retrospectively evaluated to con-
firm cluster formation.
Follow-up
Complication rates within 90 days after surgery were reported
following the Clavien-Dindo score and were scored per pa-
tient [17].
The overall survival was determined with a maximum fol-
low up of 6 years and an average follow up of 33 months. The
overall survival was also determined for different malignan-
cies in different anatomical indications stratified by pN0 R0
and pN+ R0 (N = nodal status and R0 = resection margin neg-
ative). This was presented in Kaplan Meier curves (using R
statistical software; R Development Core Team, 2008,
Vienna, Austria). To yield homogenous patient groups, in
the group of skin malignancies only patients with melanoma
were included. In the penile cancer group only the SCC pa-
tients were included and this was also the case for the patients
with tumors located on the vulva. For the prostate cancer
patients we reported the biochemical recurrence rate (BCR)-
free (prostate specific antigen (PSA) >0.01 ng/ml) survival as
indication of disease-free survival [5].
False negative patients were defined as patients with LN
recurrence during follow up and negative SN in the originally
explored LN basin and negative non-SN at time of primary
surgery [18]. Patients with synchronous primary tumor recur-
rence and LN recurrence were excluded from this calculation.
Because FNR calculations are based on tumor containing SNs
that were missed during resection (note: no attempts were
made to resect draining lymphatic vessels), patients that pre-
sented metastases within lymphatic vessels (so-called in-
transit metastases) on follow-up were excluded from the
FNR calculation.
To allow for comparison between the group where blue dye
was used and only the hybrid tracer was used, the LN recur-
rences were determined on a per patient basis. For the SN
penis and vulva procedures the FNR per groin was also re-
ported. When applicable, the FNR rates were also reported
without inclusion of the first 15 procedures, which were con-
sidered as an initial learning curve with the technology.
Statistical analysis
The intraoperative SN detection rates were calculated as per-
centages of SNs. Fluorescence detection was compared to
blue detection and gamma detection for the overall group,
and per indication. Associations of fluorescence detection
in vivo and ex vivo with BMI of the patient were investigated
with logistic regression, using the Huber-White method to
adjust the variance-covariance matrix to correct for correlated
responses from nodes clustered within the same patient (using
R function robcov from package rms) [19]. A 95% confidence
interval (CI) was given, and a p-value ≤0.05 was considered
significant.
Wilcoxon’s rank sum tests were performed to test associa-
tions between whether primary tumor site removal was before
or after SN biopsy and SN detection rates. The same test was
used to assess associations of a 1- or 2-day protocol with the
SN detection rates and the gamma counts measured by the
gamma probe. A log-rank test was used to analyze the statis-
tical differences between the Kaplan Meier curves.
Results
Preoperative SN mapping via nuclear imaging
In the SI section, the preoperative-imaging findings are de-
scribed. In total 1,327 SN-related hotspots were identified in
these images.
Intraoperative SN identification rates enabled
by surgical guidance modalities
The intraoperative detection rates using radioguidance, fluo-
rescence and blue dye are summarized in Fig. 2, Table 1 and
Table SI2. In total 1,643 SNs specimens (containing 1,938
SNs) were surgically removed.
Of the SNs that were surgically removed, 99% (in vivo and
ex vivo combined) could be detected using gamma tracing.
This was the leading guidance technology and provided a
benchmark for both blue dye and fluorescence. Overall, using
the hybrid tracers’ fluorescence signature, the SNs could be
optically identified in >95% (in vivo and ex vivo combined)
of the cases (combined in vivo and ex vivo examination in the
surgical theater). The anatomy of the basin in which the SNs
were situated did not influence these find rates (Fig. 2). The
hybrid tracer nodal dissections did not suffer from contamina-
tion of the surgical field as a result of tracer leakage from the
lymphatic system. Of the SN specimens 12% (194/1643) were
superficially located and could be resected without the use of
the fluorescence signature (note: these SNs did clearly express
a fluorescent signature). Despite the slightly lower detection
rate > 95% vs. 99%, in more complex anatomical locations,
e.g. the head-and-neck or pelvic area, the fluorescence signa-
ture of the hybrid tracer was valued for its superior spatial
resolution and the ability to visualize the SNs with the ana-
tomical context (Figure SI2). Potential damage to surrounding
structures withheld the surgeon from resection in 2.2% (29/
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1327) of the SN-related hotspots identified on SPECT/CT, e.g.
in the neck or pararectal space. In these cases, despite a clear
gamma read-out of the same tracer, the inability to detect a
fluorescence signal indicated the SNs were located >0.5–1 cm
deep within the tissue. This fluorescence-based depth-
estimation helped improve a benefit/risk balance on which
the decision was made to abandon further dissection in these
areas. In the head and neck, groin and pelvis, this feature of the
hybrid tracer made the operating surgeon generally rely more
on intraoperative fluorescence guidance than on intraoperative
Fig. 2 Optical guidance enabled by the hybrid tracer and blue dye. a
Typical examples of procedures combining use of blue dye and the
hybrid tracer ICG-99mTc-nanocolloid in the head-and-neck region and
groin. b Typical examples of procedures using only the hybrid tracer
for optical guidance (head-and-neck and pelvic region). The second
column demonstrates what is seen by eye, while the third column
provides insight into the signal obtained via fluorescence imaging with
a (laparoscopic) near-infrared dedicated fluorescence camera
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radioguidance. In eight patients (1.6% of total) radioguidance
could not distinguish the SN from the injection site, yet these
SNs were preoperatively identified by SPECT/CT and could
readily be resected under fluorescence guidance. When SNs
were located deeper than 0.5–1 cm from the tissue surface,
fluorescence guidance was unreliable and a combination of
the SPECT/CT findings and the radioactive signature of the
hybrid tracer were instrumental for the nodal localization.
For the procedures where blue dye was used, a wide
variation in blue stained SNs was observed in the SNs
(20–72%; n = 300; 950 SNs; Fig. 3). Blue dye was most
helpful in the axilla (72%), but proved to be of limited
value in the head-and-neck area (23%) as well as the arm
and shoulder (20%). Blue dye-based find rates were sig-
nificantly poor compared to those obtained with the fluo-
rescent signature of the hybrid tracer (p-value <0.001).
Merely 1% (9 SNs; in vivo and ex vivo combined) was
dissected based on blue coloration only (and SI Table 3).
Hence the availability of the hybrid tracer (meaning the
availability of a fluorescence and/or a radioactive signa-
ture) in the SNs was considered to provide superior
>95% guidance compared to blue dye.
The relation between pre-operative and intraoperative SN
find rates, the influence of the surgical resection order (see
Figure SI1) and BMI (see Figure SI2) on the surgical guidance
procedure are described in the SI section.
Table 1 Fluorescence-, blue- and radioactivity-based detection rate per indication (see also Fig. 2)
Parameter Skin malignancies body Head-and-neck skin malignancies Oral cavity Penis Prostate Vulva Total
In vivo detection rates
Blue used Yes Yes No Yes No Yes No Yes Total
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SNs not evaluated for radioactivity 0 0 8 0 43 8 45 1 105
Total (in vivo and ex vivob combined)
Blue used Yes Yes No Yes No Yes No Yes






























































































SNs not evaluated for radioactivity 0 0 0 0 9 6 0 1 16
SN sentinel node
a Due to the hybrid nature of the tracer the fluorescence and radioactive signatures are directly related
b Ex vivo validation of the fluorescence signal because of tissue attenuationwhereby the in vivo detection of the fluorescent signal could be hampered. Ex
vivo the SNs are more exposed and as such the fluorescence detection increases
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Fig. 3 Intraoperative detection rates for the different surgical guidance
modalities used. a Blue dye-based SN identification percentages in
patients who received blue dye subsequently to the hybrid tracer (total
n = 300). b Fluorescence-based SN identification percentages (total n =
501). c Radioactivity-based SN identification percentages (total n = 501).
d and e respectively depict the fluorescence-based and radioactivity based
SN identification percentages in the patient groups that did not receive
blue dye (total n = 201). Detection rates are provided for different regions:
i) head and neck area, ii) arm and trunk, iii) axilla, iv) inguinal area and v)
pelvic region
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Pathological evaluation
From the excised 1,643 SN specimens (containing single LNs
or LN clusters), 1938 LNs were harvested at pathology. In
Table SI2 the percentage of tumor positive SNs is reported.
In the SI a further description of the tumor find rate (TFR) is
provided.
Follow-up
The complication grade score according to Clavien-Dindo
ranged from I–V in this study cohort and was highest in the
group of penile cancer patients (Table SI4). In none of the 495
patients did adverse effects occur that could be related to the
use of the hybrid tracer or blue dye. Also, there was no corre-
lation seen between the removal of additional SNs and occur-
rence of procedure-related complications (p-value 0.478). The
overall survival results are provided in the SI section
(Figure SI3).
The average follow up in this study was limited to
33 months. In pN0 R0 patients (n = 321; 65%), the LN
recurrence-free survival varied from 93 to 100% for the vari-
ous indications, with an average of 93% at two-year follow-up
(Fig. 4a, b). In the prostate cancer patients, a BCR-free sur-
vival of 90% (CI 73–100%) was found at 2-year follow-up
(Fig. 4c). No LN recurrences occurred in patients with mela-
noma on the body or vulvar cancer. In the penile cancer pa-
tients, the LN recurrence-free survival rate was the lowest
(77%) at 5-year follow-up.
In a relatively small group of pN0 R0 patients with head-
and-neck melanoma, wherein the hybrid tracer was used in
combination with (n = 19) or without (n = 80) blue dye, we
were able to study if use of blue dye had an influence on LN
recurrence-free survival. The group wherein the hybrid tracer
alone was used had a 97% (CI 93%-100%) LN recurrence-
free survival probability, while the group with the hybrid trac-
er in combination with blue dye had a slightly lower LN
recurrence-free survival of 94% (CI 84-100%). Both groups
were comparable for T-stage. These findings indicate that use
of blue dye next to the hybrid tracer does not lead to a better
prognosis (Fig. 4d).
In the overall population, ten isolated LN recurrences (2%)
were reported, yielding a combined FNR of 14% (see SI Table 4
for the FNRs of the individual procedures). Interestingly, false
negative findings (during follow up) of oral cavity patients oc-
curred in the first 15 cases. After this learning curve, the com-
bined FNR decreases to 10.3% (Table SI4). A low FNR was
found in the melanoma body group (0%) and a modest FNR
(7%) in the melanoma head-and-neck group. The obtained
values were lower than the weighted literature FNRs for head-
and-neck melanoma, which averaged 12.5% (range 0–34%)
[20]. The FNR in oral cavity cancer (22%) was in line with
the range previously reported (9–29%) [21, 22]. In the penile
cancer group the FNR was 16%, which was lower than the
initial report of the sentinel node biopsy for penile cancer
(22%) described by Tanis et al. [23]. The FNR rate for penile
cancer further dropped to 14% following exclusion of the re-
sentinel node procedures, which indicates the 16 repeat SN pro-
cedures in patients with local recurrence had a negative influ-
ence on the FNR (Table SI4). The 0% FNR we found for the
vulvar cancer patients is in line with the report of Van der Zee
et al. (2.3–3%) [24]. The FNR of the SN procedure in the pros-
tate cancer group compared to the extended pelvic LN dissection
(ePLND) was 11.3%, again comparable to earlier reports [4].
Discussion
The present longitudinal study of a 495-patient cohort indi-
cates that the generation of a hybrid set-up that includes fluo-
rescence guidance in an otherwise standard SN-procedure cre-
ates value for the operating surgeons by: (1) improving optical
guidance compared to blue dye (>95% vs. 20–72%, respec-
tively (Table 1; p-value < 0.001), (2) providing benefit over
radiotracing as a result of visualizing the SNs within their
anatomical context, a feature that was particularly valuable
in complex anatomies (95% of the SNs (Table 1)), (3) provid-
ing depth estimation (>0.5–1 cm) of the nodal location, which
helped prevent surgery related side effects in 2.2% of the SNs
and (4) supporting the surgical identification of LNs that re-
side next to the injection site (1.6% of the SNs). Unlike blue
dye, the value of the hybrid tracer was not confined to the
anatomical location wherein the procedure was applied, sur-
gical timing, the order of resection (primary tumor vs. SN), or
the surgical setting used (open or laparoscopic). Hence,
through use of the hybrid tracer, SN procedures can be per-
formed in a uniform manner, allowing expansion of the tech-
nology to non-traditional SN indications.
The hybrid approach described provided the ability to per-
form radioguidance and enhance it by fluorescence imaging of
the exact same features. This resulted in a further refinement
of the surgical SN identification, e.g. the ability to surgical-
ly identify SNs in close location to the injection site helped
improve coherence with the surgical findings and the SN-
related hotspots detected by preoperative SPECT/CT. The
synergistic approach also yielded enhanced intraoperative
SN find rates, e.g. during surgery 24% more nodes were iden-
tified [13, 16]. In contrast to what has been reported for the use
of Bfree^ ICG, the hybrid tracer did not show leakage into the
surgical field [25]. Unfortunately, fluorescence imaging (even
in the near-infrared region of the light spectrum) suffers from
tissue attenuation when compared to radioguidance technolo-
gies [11]. The difference between in vivo and ex vivo fluores-
cence detection rates (Table 1 and Table SI3) underline that
radioguidance remains essential for in vivo SN localization
and that ex vivo validation remains critical to assess the
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presence of fluorescence [10]. This effect increases with an
increase in BMI (see Figure SI2). Uniquely, in some cases
lack of fluorescence detection was considered predictive for
the depth in the tissue at which the SN resided.
One aspect that we have not addressed in this patient cohort
was the differentiation of SNs from higher echelon nodes via
visualization of the afferent lymphatic ducts, a blue dye tech-
nique commonly performed by expert surgeons [7]. Although
the fluorescence guidance modalities used in this study were
able to visualize the afferent lymphatic ducts [16], visualiza-
tion of these ducts was not relied upon as a routine tool due to
the labor intensive exposure of the ducts. We recently reported
that lymph duct visualization becomes much more straight
forward with next generation fluorescence guidance cameras
[26]. When such hardware improvements are integrated, use
of the hybrid tracer strengthens a recent statement by Van der
Ploeg et al. who suggest that blue dye may potentially be
omitted in SN biopsy for melanoma [27]. The LN blue dye
Fig. 4 Lymph node- and biochemical recurrence curves. In a and b the
LN recurrence curves are shown for the total group and per indication,
respectively. c Biochemical recurrence free survival of pN0 R0 prostate
cancer patients. To relate outcome to the use of the hybrid tracer with or
without the use of blue dye, recurrence rates are shown for the head
melanoma group. d LN recurrence rates for R0N0 head-and-neck
melanoma patients (p = 0.29)
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dependent free recurrences survival we report for a homoge-
nous head and neck melanoma population (Fig. 4d) also indi-
cates that use of blue dye did not positively influence
outcome.
The follow up data provided for the hybrid SN procedure is
positive (Fig. 4 and Figure SI3) and an overall false negative
rate (FNR) of 10.1% (Table SI4) is acceptable, but from the
current data it is not yet possible to conclude whether use of
the hybrid tracer improves the oncological outcome. Limiting
herein is the average follow up time of 33 months. There also
were clear indications that in complex anatomies the proce-
dure includes a learning curve, which was also reported pre-
viously [28]. Given the complexity of the diagnostic SN pro-
cedure, the limited tumor find-rates, and the dependence on
factors that extend beyond the operating theater, e.g. tracer
administration and pathological accuracy, we wonder whether
expecting such improvements would even be realistic.
Following the technical evolution of tracers and surgical guid-
ance modalities, it seems that further refinement of the onco-
logical outcome requires a critical look at the patient inclusion,
tracer deposition, and means of pathological evaluation. In
this cohort, for example, some patients were staged with a
higher T-stage than those described in the treatment guidelines
of the different malignancies, which could have negatively
influenced the findings (Table SI1). For the tracer deposition,
earlier and ongoing studies indicate that its location directly
relates to the lymphatic drainage and thus refinements in this
area could help improve the ability to detect lymphatic metas-
tasis [29]. Finally, the relation between the FNR and the accu-
racy of the surgical guidance procedure is not a direct one as
the FNR is also highly dependent on the quality of the patho-
logical accuracy, in particular when micro-metastases occur
[30]. Hence advances in the pathological examination of SN
specimens could also help to improve the procedure.
All surgeons involved in the present study had previous
experience with SN-procedures based on radioguidance (99m
Tc-nanocolloid) and valued the more detailed guidance ob-
tained using ICG-99mTc-nanocolloid. Given the study set-up
(order: first radioguidance, e.g. SPECT imaging, use portable
gamma camera and gamma tracing, followed by blue dye
detection and lastly, fluorescence imaging), the present find-
ings all used radioguidance (the modality used for preopera-
tive imaging, e.g. SPECT/CT and the surgical modality that
provides superior (in-depth) detection sensitivity) as reference
[8]. Future randomized studies that blind the operating sur-
geon to different aspects in the hybrid image guidance proce-
dure, e.g. different aspects of radioguidance, could help to
provide more detailed insight into the clinical value of the
individual components of the technology. It should be noted
that the hybrid tracer design solely has the purpose to extend
routine radioguidance with fluorescence guidance, rather than
replace radioguidance approaches with fluorescence guid-
ance. Moreover, the limited tissue penetration of fluorescence
guidance prevents its use for surgical planning [30], a critical
aspect in SN procedures. Nevertheless, randomized blinded
studies are currently being conducted to accurately determine
the dependency of fluorescence guidance on the information
provided by nuclear medicine. Alternative features that could
be valuable to measure in future trials are operating time and
the surgeon’s confidence in decision making.
Conclusion
This study underlines that the proposed hybrid SN approach,
which uses the hybrid tracer ICG-99mTc-nanocolloid, not only
provides preoperative SN mapping but also allows for superi-
or optical surgical guidance compared to blue dye.
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